Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types.

"Competing interests: JS and SB received institutional research funding from Lunit, Inc. HS, SP, SSh, YL, CHO, Seulki Kim, CO, Sukjun Kim, GP, SSo, WJ, SA and C-YO are employees of Lunit, Inc. Y-JB. is a Consultant/Advisory Board member for Merck Sharp and Dohme (MSD), Merck Serono, Daiichi-Sankyo, Astellas, Alexo Oncology, Samyang Biopharm, Hanmi, Daewoong, and Amgen, and received institutional research grants for clinical trials from Genentech/Roche, MSD, Merck Serono, Daiichi Sankyo, Astellas, and Amgen in the past 3 years. Other authors declare no potential conflicts of interest."

"Funding: Funding for this study was provided by Lunit Inc., with additional infrastructural support from the Stanford Center for Artificial Intelligence in Medicine & Imaging (AIMI) and the Department of Pathology, Stanford University School of Medicine. JS additionally received support from the United States National Cancer Institute (NCI), National Institutes of Health (NIH) (R01 CA270437)."